Canine atopische Dermatitis

Zusammenfassung

Die canine atopische Dermatitis (caD) ist eine genetisch bedingte, chronisch-entzündliche Hautkrankheit, bei der Defekte der Hautbarriere, Allergensensibilisierung und mikrobielle Dysbiose eine Rolle spielen. Sie äußert sich v. a. durch Juckreiz und tritt meist im jungen Alter zum ersten Mal auf. Die Diagnose erfolgt durch gründliche Anamneseerhebung, klinische Untersuchung und den Ausschluss von Differentialdiagnosen. Die Auswahl der Therapieoptionen zur Behandlung der caD ist von verschiedenen Faktoren abhängig und umfasst systemische und topische Medikamente zur Immunmodulation.

Da die Krankheit eine erhebliche Belastung der Besitzer*innen mit sich bringen kann, ist eine umfassende, verständliche und nachhaltige Aufklärung durch Tierärzt*innen notwendig, um Betroffene besser in das Krankheitsmanagement einzubinden und langfristig zu entlasten.

Die langfristige Behandlung der caninen atopischen Dermatitis erfordert eine hohe Therapietreue sowie ausreichende Gesundheitskompetenz der Tierbesitzer*innen, da sie die komplexen, oftmals aufwändigen topischen Behandlungen eigenverantwortlich anpassen und durchführen müssen. Gezielte Schulungen der betroffenen Besitzer*innen können das Verständnis der Erkrankung, das Selbstmanagement und damit die Lebensqualität sowie den Behandlungserfolg deutlich verbessern.

Abstract

Canine atopic dermatitis (caD) is a chronic, genetic inflammatory skin disease involving defects in the skin barrier, allergen sensitization, and microbial dysbiosis. It is primarily characterized by pruritus and typically begins at a young age. A diagnosis is reached by clinical examination, recording a thorough medical history, and ruling out differential diagnoses. Treatment options for caD depend on various factors and include systemic and topical drugs for immunomodulation.

As this disease may place a considerable burden on owners, it is necessary for veterinarians to provide comprehensive, understandable and sustainable education in order to improve client involvement in its management as well as offering long-term support.

Long-term therapy of caD requires pet owners to develop a high level of adherence to treatment and sufficient health literacy, as they must carry out and at times adapt complex, mostly topical treatments themselves. Targeted education for affected owners can significantly improve their understanding of the disease and self-management, thereby improving quality of life and treatment success.

Schlüsselwörter

Allergie - Schulung - Therapie - Selbstständigkeit - Management

Keywords

Allergy - education - therapy - autonomy - management

Publication History

Received: 07 July 2025

Accepted: 23 October 2025

Article published online:
28 November 2025

• Literatur

• 1 Hillier A, Griffin CE. The ACVD task force on canine atopic dermatitis (I): incidence and prevalence. Vet Immunol Immunopathol 2001; 81: 147-151
• 2 Drechsler Y, Dong C, Clark DE. et al. Canine Atopic Dermatitis: Prevalence, Impact, and Management Strategies. Vet Med (Auckl) 2024; 15: 15-29
• 3 Griffin CE, DeBoer DJ. The ACVD task force on canine atopic dermatitis (XIV): clinical manifestations of canine atopic dermatitis. Vet Immunol Immunopathol 2001; 81: 255-269
• 4 Eisenschenk M. Phenotypes of Canine Atopic Dermatitis. Current Dermatology Reports 2020; 9: 175-180
• 5 Olivry T, DeBoer DJ, Favrot C. et al. Treatment of canine atopic dermatitis: 2015 updated guidelines from the International Committee on Allergic Diseases of Animals (ICADA). BMC Vet Res 2015; 11: 210
• 6 Lifschitz C. The impact of atopic dermatitis on quality of life. Ann Nutr Metab 2015; 66: 34-40
• 7 Linek M, Favrot C. Impact of canine atopic dermatitis on the health-related quality of life of affected dogs and quality of life of their owners. Vet Dermatol 2010; 21: 456-462
• 8 Eisenschenk MC, Hensel P, Saridomichelakis MN. et al. Introduction to the ICADA 2023 canine atopic dermatitis pathogenesis review articles and updated definition. Vet Dermatol 2024; 35: 3-4
• 9 Bizikova P, Pucheu-Haston CM, Eisenschenk MN. et al. Review: Role of genetics and the environment in the pathogenesis of canine atopic dermatitis. Vet Dermatol 2015; 26: 95-e26
• 10 Zur G, Ihrke PJ, White SD. et al. Canine atopic dermatitis: a retrospective study of 266 cases examined at the University of California, Davis, 1992–1998. Part I. Clinical features and allergy testing results. Vet Dermatol 2002; 13: 89-102
• 11 Olivry T, Mueller RS. Critically appraised topic on adverse food reactions of companion animals (7): signalment and cutaneous manifestations of dogs and cats with adverse food reactions. BMC Vet Res 2019; 15: 140
• 12 Olivry T, Deboer DJ, Prelaud P. et al. Food for thought: pondering the relationship between canine atopic dermatitis and cutaneous adverse food reactions. Vet Dermatol 2007; 18: 390-391
• 13 Marsella R, De Benedetto A. Atopic Dermatitis in Animals and People: An Update and Comparative Review. Vet Sci 2017; 4
• 14 Mueller RS, Olivry T. Critically appraised topic on adverse food reactions of companion animals (4): can we diagnose adverse food reactions in dogs and cats with in vivo or in vitro tests?. BMC Vet Res 2017; 13: 275
• 15 Wilhem S, Kovalik M, Favrot C. Breed-associated phenotypes in canine atopic dermatitis. Vet Dermatol 2011; 22: 143-149
• 16 Nuttall TJ, Marsella R, Rosenbaum MR. et al. Update on pathogenesis, diagnosis, and treatment of atopic dermatitis in dogs. J Am Vet Med Assoc 2019; 254: 1291-1300
• 17 Hensel P, Santoro D, Favrot C. et al. Canine atopic dermatitis: detailed guidelines for diagnosis and allergen identification. BMC Vet Res 2015; 11: 196
• 18 DeBoer DJ, Hillier A. The ACVD task force on canine atopic dermatitis (XV): fundamental concepts in clinical diagnosis. Vet Immunol Immunopathol 2001; 81: 271-276
• 19 Favrot C, Steffan J, Seewald W. et al. A prospective study on the clinical features of chronic canine atopic dermatitis and its diagnosis. Vet Dermatol 2010; 21: 23-31
• 20 Outerbridge CA, Jordan TJM. Current Knowledge on Canine Atopic Dermatitis: Pathogenesis and Treatment. Adv Small Anim Care 2021; 2: 101-115
• 21 Gedon NKY, Mueller RS. Atopic dermatitis in cats and dogs: a difficult disease for animals and owners. Clin Transl Allergy 2018; 8: 41
• 22 Olivry T, DeBoer DJ, Favrot C. et al. Treatment of canine atopic dermatitis: 2010 clinical practice guidelines from the International Task Force on Canine Atopic Dermatitis. Vet Dermatol 2010; 21: 233-248
• 23 Olivry T, Bizikova P. A systematic review of randomized controlled trials for prevention or treatment of atopic dermatitis in dogs: 2008–2011 update. Vet Dermatol 2013; 24: 97-117 e125-116
• 24 Steffan J, Favrot C, Mueller R. A systematic review and meta-analysis of the efficacy and safety of cyclosporin for the treatment of atopic dermatitis in dogs. Vet Dermatol 2006; 17: 3-16
• 25 Nuttall T, Reece D, Roberts E. Life-long diseases need life-long treatment: long-term safety of ciclosporin in canine atopic dermatitis. Vet Rec 2014; 174: 3-12
• 26 Gonzales AJ, Bowman JW, Fici GJ. et al. Oclacitinib (APOQUEL((R))) is a novel Janus kinase inhibitor with activity against cytokines involved in allergy. J Vet Pharmacol Ther 2014; 37: 317-324
• 27 Kuntz EA, Gabor L, Toutain CE. Safety of ilunocitinib tablets (Zenrelia) after once daily oral administration in dogs. BMC Vet Res 2025; 21: 144
• 28 Carmi-Levy I, Homey B, Soumelis V. A modular view of cytokine networks in atopic dermatitis. Clin Rev Allergy Immunol 2011; 41: 245-253
• 29 Cosgrove SB, Wren JA, Cleaver DM. et al. Efficacy and safety of oclacitinib for the control of pruritus and associated skin lesions in dogs with canine allergic dermatitis. Vet Dermatol 2013; 24: 479-e114
• 30 Forster S, Trout CM, Despa S. et al Efficacy and field safety of ilunocitinib for the control of atopic dermatitis in client-owned dogs: A multicentre, double-masked, randomised, placebo-controlled clinical trial. Vet Dermatol 2025; doi:10.1111/vde.13344
• 31 Little PR, King VL, Davis KR. et al A blinded, randomized clinical trial comparing the efficacy and safety of oclacitinib and ciclosporin for the control of atopic dermatitis in client-owned dogs. Vet Dermatol 2015; 26 23–30 e27-e28
• 32 Forster S, Boegel A, Despa S. et al. Comparative efficacy and safety of ilunocitinib and oclacitinib for the control of pruritus and associated skin lesions in dogs with atopic dermatitis. Vet Dermatol 2025; 36: 165-176
• 33 Tominaga M, Takamori K. Peripheral itch sensitization in atopic dermatitis. Allergol Int 2022; 71: 265-277
• 34 Michels GM, Ramsey DS, Walsh KF. et al. A blinded, randomized, placebo-controlled, dose determination trial of lokivetmab (ZTS-00103289), a caninized, anti-canine IL-31 monoclonal antibody in client owned dogs with atopic dermatitis. Vet Dermatol 2016; 27: 478-e129
• 35 Michels GM, Walsh KF, Kryda KA. et al. A blinded, randomized, placebo-controlled trial of the safety of lokivetmab (ZTS-00103289), a caninized anti-canine IL-31 monoclonal antibody in client-owned dogs with atopic dermatitis. Vet Dermatol 2016; 27: 505-e136
• 36 Kasper B, Zablotski Y, Mueller RS. Long-term use of lokivetmab in dogs with atopic dermatitis. Vet Dermatol 2024; doi:10.1111/vde.13286
• 37 Dell DL, Griffin CE, Thompson LA. et al. Owner assessment of therapeutic interventions for canine atopic dermatitis: a long-term retrospective analysis. Vet Dermatol 2012; 23: 228-e247
• 38 Hsiao YH, Chen C, Willemse T. Effects of cetirizine in dogs with chronic atopic dermatitis: a randomized, double blind, placebo-controlled trial. J Vet Sci 2016; 17: 549-553
• 39 Eichenseer M, Johansen C, Mueller RS. Efficacy of dimetinden and hydroxyzine/chlorpheniramine in atopic dogs: a randomised, controlled, double-blinded trial. Vet Rec 2013; 173: 423
• 40 DeBoer DJ, Griffin CE. The ACVD task force on canine atopic dermatitis (XXI): antihistamine pharmacotherapy. Vet Immunol Immunopathol 2001; 81: 323-329
• 41 Nuttall T, Mueller R, Bensignor E. et al. Efficacy of a 0.0584% hydrocortisone aceponate spray in the management of canine atopic dermatitis: a randomised, double blind, placebo-controlled trial. Vet Dermatol 2009; 20: 191-198
• 42 Marsella R, Nicklin CF, Saglio S. et al. Investigation on the clinical efficacy and safety of 0.1% tacrolimus ointment (Protopic) in canine atopic dermatitis: a randomized, double-blinded, placebo-controlled, cross-over study. Vet Dermatol 2004; 15: 294-303
• 43 Curtis C. Use and abuse of topical dermatological therapy in dogs and cats Part 1. Shampoo therapy. In Practice 1998; 20: 244-251
• 44 Saevik BK, Bergvall K, Holm BR. et al. A randomized, controlled study to evaluate the steroid sparing effect of essential fatty acid supplementation in the treatment of canine atopic dermatitis. Vet Dermatol 2004; 15: 137-145
• 45 Muller MR, Linek M, Lowenstein C. et al. Evaluation of cyclosporine-sparing effects of polyunsaturated fatty acids in the treatment of canine atopic dermatitis. Vet J 2016; 210: 77-81
• 46 Schafer L, Thom N. A placebo-controlled, double-blind study evaluating the effect of orally administered polyunsaturated fatty acids on the oclacitinib dose for atopic dogs. Vet Dermatol 2024; 35: 408-417
• 47 Paterson S. Additive benefits of EFAs in dogs with atopic dermatitis after partial response to antihistamine therapy. J Small Anim Pract 1995; 36: 389-394
• 48 Rostaher A, Morsy Y, Favrot C. et al. Comparison of the Gut Microbiome between Atopic and Healthy Dogs-Preliminary Data. Animals (Basel) 2022; 12
• 49 Bousquet J, Lockey R, Malling HJ. Allergen immunotherapy: therapeutic vaccines for allergic diseases. A WHO position paper. J Allergy Clin Immunol 1998; 102: 558-562
• 50 Ramio-Lluch L, Brazis P, Ferrer L. et al. Allergen-specific immunotherapy in dogs with atopic dermatitis: is owner compliance the main success-limiting factor?. Vet Rec 2020; 187: 493
• 51 Loewenstein C, Mueller RS. A review of allergen-specific immunotherapy in human and veterinary medicine. Vet Dermatol 2009; 20: 84-98
• 52 Mueller RS, Zablotski Y, Baumann K. et al. A randomised, double-blinded comparison between subcutaneous rush and intralympathic allergen immunotherapy induction in atopic dogs. Vet Dermatol 2023; 34: 91-98
• 53 Fischer NM, Rostaher A, Favrot C. A comparative study of subcutaneous, intralymphatic and sublingual immunotherapy for the long-term control of dogs with nonseasonal atopic dermatitis. Vet Dermatol 2020; 31: 365-e396
• 54 Fennis EEM, van Damme CMM, Schlotter YM. et al. Efficacy of subcutaneous allergen immunotherapy in atopic dogs: A retrospective study of 664 cases. Vet Dermatol 2022; 33: 321-e375
• 55 DeBoer DJ, Hillier A. The ACVD task force on canine atopic dermatitis (XVI): laboratory evaluation of dogs with atopic dermatitis with serum-based "allergy" tests. Vet Immunol Immunopathol 2001; 81: 277-287
• 56 Olivry T, Banovic F. Treatment of canine atopic dermatitis: time to revise our strategy. Vet Dermatol 2019; 30: 87-90
• 57 Spitznagel MB, Solc M, Chapman KR. et al. Caregiver burden in the veterinary dermatology client: comparison to healthy controls and relationship to quality of life. Vet Dermatol 2019; 30: 3-e2
• 58 Spitznagel MB, Jacobson DM, Cox MD. et al. Caregiver burden in owners of a sick companion animal: a cross-sectional observational study. Vet Rec 2017; 181: 321
• 59 Spitznagel MB, Hillier A, Gober M. et al. Treatment complexity and caregiver burden are linked in owners of dogs with allergic/atopic dermatitis. Veterinary Dermatology 2021; 32
• 60 Zarit SH, Reever KE, Bach-Peterson J. Relatives of the impaired elderly: correlates of feelings of burden. Gerontologist 1980; 20: 649-655
• 61 Spitznagel MB, Carlson MD. Caregiver Burden and Veterinary Client Well-Being. Vet Clin North Am Small Anim Pract 2019; 49: 431-444
• 62 Noli C, Minafo G, Galzerano M. Quality of life of dogs with skin diseases and their owners. Part 1: development and validation of a questionnaire. Vet Dermatol 2011; 22: 335-343
• 63 Spitznagel MB, Jacobson DM, Cox MD. et al. Predicting caregiver burden in general veterinary clients: Contribution of companion animal clinical signs and problem behaviors. Vet J 2018; 236: 23-30
• 64 Fernandes B, Cavaco A, Pinto M. et al Are images worth a thousand words? A preliminary study testing a video for owner education in canine atopic dermatitis. Vet Dermatol 2023; doi:10.1111/vde.13200
• 65 Shaw JR, Adams CL, Bonnett BN. et al. Use of the roter interaction analysis system to analyze veterinarian-client-patient communication in companion animal practice. J Am Vet Med Assoc 2004; 225: 222-229
• 66 Coe JB, Adams CL, Bonnett BN. A focus group study of veterinarians' and pet owners' perceptions of veterinarian-client communication in companion animal practice. J Am Vet Med Assoc 2008; 233: 1072-1080
• 67 Albuquerque CS, Bauman BL, Rzeznitzeck J. et al. Priorities on treatment and monitoring of diabetic cats from the owners' points of view. J Feline Med Surg 2020; 22: 506-513
• 68 Belshaw Z, Robinson NJ, Dean RS. et al. Motivators and barriers for dog and cat owners and veterinary surgeons in the United Kingdom to using preventative medicines. Prev Vet Med 2018; 154: 95-101
• 69 Carroll CL, Feldman SR, Camacho FT. et al. Better medication adherence results in greater improvement in severity of psoriasis. Br J Dermatol 2004; 151: 895-897
• 70 Krejci-Manwaring J, Tusa MG, Carroll C. et al. Stealth monitoring of adherence to topical medication: adherence is very poor in children with atopic dermatitis. J Am Acad Dermatol 2007; 56: 211-216
• 71 Barbarot S, Bernier C, Deleuran M. et al. Therapeutic patient education in children with atopic dermatitis: position paper on objectives and recommendations. Pediatr Dermatol 2013; 30: 199-206
• 72 Ratzan S, Parker R, Selden C. et al. National Library of Medicine Current Bibliographies in Medicine: Health Literacy. Bethesda, MD: National Institutes of Health; 2000
• 73 Moore SA. Read All About It: Health Literacy and Veterinary Client Educational Materials. Topics in Companion Animal Medicine 2018; 33
• 74 de Bes J, Legierse CM, Prinsen CA. et al. Patient education in chronic skin diseases: a systematic review. Acta Derm Venereol 2011; 91: 12-17
• 75 Armstrong AW, Kim RH, Idriss NZ. et al. Online video improves clinical outcomes in adults with atopic dermatitis: a randomized controlled trial. J Am Acad Dermatol 2011; 64: 502-507
• 76 Santer M, Muller I, Yardley L. et al. Supporting self-care for families of children with eczema with a Web-based intervention plus health care professional support: pilot randomized controlled trial. J Med Internet Res 2014; 16: e70
• 77 Coenraads PJ, Span L, Jaspers JP. et al. [Intensive patient education and treatment program for young adults with atopic eczema]. Hautarzt 2001; 52: 428-433
• 78 Staab D, Diepgen TL, Fartasch M. et al. Age related, structured educational programmes for the management of atopic dermatitis in children and adolescents: multicentre, randomised controlled trial. BMJ 2006; 332: 933-938